


<b>ISSUE DATE</b>  May 9, 2022	<b>EFFECTIVE DATE</b>  February 11, 2022	<b>NUMBER</b>  01-22-11, 05-22-03, 08-22-11, 09-22-10, 10-22-03, 30-22-07, 31-22-11, 33-22-09
<b>SUBJECT</b>  Addition of Monoclonal Antibody Product Bebtelovimab to the MA Program Fee Schedule	<b>BY</b>   Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs	

**IMPORTANT REMINDER:** All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

## **PURPOSE:**

The purpose of this bulletin is to inform Medical Assistance (MA) providers of the addition of Common Procedural Terminology (CPT) codes M0222 and M0223 to the MA Program Fee Schedule for the administration of the monoclonal antibody product for treatment of the novel coronavirus (SARS-CoV-2), effective February 11, 2022.

## **SCOPE:**

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, physician assistants, outpatient hospital clinics, home health agencies, independent medical surgical clinics, pharmacies, and renal dialysis centers enrolled in the MA Program who are authorized to administer monoclonal antibody therapies to MA beneficiaries in MA Fee-for-Service (FFS) delivery system. Providers rendering services in the MA managed care delivery system should address any coding and rate-related questions to the appropriate managed care organization.

## **BACKGROUND/DISCUSSION:**

On February 11, 2022, the United States Food and Drug Administration (FDA) issued an Emergency Use Authorization for the monoclonal antibody product Bebtelovimab for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients with a positive COVID-19 test result who are at high risk for progression to severe

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>

COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

In response, the Department of Human Services (Department) added CPT codes M0222 and M0223 to the MA Program Fee Schedule for the administration of Bebtelovimab, effective for dates of services on and after February 11, 2022.

**PROCEDURE:**

MA providers in the FFS delivery system should bill the Department for the administration of the SARS-CoV-2 monoclonal antibody product Bebtelovimab with the procedure codes and effective date identified below.

<b>Procedure Code</b>	<b>Description</b>	<b>Effective Date</b>	<b>New MA Fee</b>
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	2/11/22	\$280.40
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	2/11/22	\$440.40

Attached is the fee schedule entitled, "Addition of Monoclonal Antibody Product Bebtelovimab to the MA Program Fee Schedule". The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee for the procedure codes for providers submitting MA FFS claims.

If an MA beneficiary's permanent residence is a setting that provides health care services, such as an intermediate care facility or nursing facility, that setting would qualify as a "home or residence" for purposes of billing CPT codes M0223. However, if an MA beneficiary is only in that location temporarily (such as if the MA beneficiary has a permanent home but is in a post-acute stay in a nursing facility), the setting would not be considered the MA beneficiary's "home or residence", so CPT code M0223 should not be billed. Inpatient locations, such as inpatient hospitals, inpatient psychiatric hospitals, and inpatient rehabilitation hospitals, would never qualify as the "home or residence" for purposes of CPT code M0223.

Providers may not bill the MA Program for the monoclonal antibody product they receive at no cost, including those purchased by the federal government. MA providers who pay for the product may bill the Department by indicating, on the claim submission form, the appropriate National Drug Code for the product.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx>.

**ATTACHMENT:**

Addition of Monoclonal Antibody Product Bectelovimab to the MA Program Fee Schedule

**Addition of Monoclonal Antibody Product Bebtelovimab to the Medical Assistance Program Fee Schedule,  
Effective February 11, 2022**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	01	017	23			\$280.40	No	once per day
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	01	183	22			\$280.40	No	once per day
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	08	082	49			\$280.40	No	once per day
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	30	300	65			\$280.40	No	once per day
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	31	All	11, 23, 31, 32, 99			\$280.40	No	once per day
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	01	183	12			\$440.40	No	once per day
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	05	050	12			\$440.40	No	once per day

M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	08	082	12			\$440.40	No	once per day
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	09	All	12			\$440.40	No	once per day
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	10	100	12			\$440.40	No	once per day
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	30	300	12			\$440.40	No	once per day
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	31	All	12			\$440.40	No	once per day

M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	33	335	12		\$440.40	No	once per day
-------	---	----	-----	----	--	----------	----	--------------